fluorouracil has been researched along with Glial Cell Tumors in 105 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a phase I study to estimate the maximum tolerated dose and describe the dose-limiting toxicities and pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy to children with newly diagnosed brainstem or high-grade gliomas." | 9.17 | Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. ( Banerjee, A; Blaney, SM; Boyett, JM; Brownstein, C; Chintagumpala, M; Gururangan, S; Hussain, S; Kilburn, LB; Kocak, M; Kun, L; Meneses-Lorente, G; Paulino, AC; Schaedeli Stark, F; Thompson, PA, 2013) |
| " The strategy was evaluated initially to provide localized and sustained delivery of the radiosensitizer 5-fluorouracil (5-FU) after patients underwent surgical resection of malignant glioma." | 9.11 | Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. ( Benoit, JP; Boisdron-Celle, M; Delhaye, M; Faisant, N; Fournier, D; Jadaud, E; Menei, P; Michalak, S, 2004) |
| "This study was a randomized, multicenter Phase II trial comparing the effect of perioperative implantation of 5-fluorouracil-releasing microspheres followed by early radiotherapy (Arm A) and early radiotherapy alone (Arm B) in patients with gross total resection of high-grade glioma." | 9.11 | Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. ( Assaker, R; Bataille, B; Bauchet, L; Benoit, JP; Capelle, L; Dorwling-Carter, D; Faisant, N; François, P; Fuentes, S; Guyotat, J; Menei, P; Paquis, P; Parker, F; Sabatier, J, 2005) |
| "Fourteen patients with malignant gliomas were entered on a phase II study of 5-fluorouracil 300-370 mg/m2 plus folinic acid 200 mg/m2 x 5 days q4 weeks." | 9.08 | A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. ( Dahrouge, S; Soltys, K; Stewart, DJ, 1995) |
| "This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)." | 9.07 | A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992) |
| " The anti-glioma effect of cyclophosphamide (CTX), 5-fluorouracil (5-FU), oxaliplatin (OXA), doxorubicin (DOX) or gemcitabine (GEM) combined with AgNTs in different glioma cell lines (U87, U251 and C6) was assessed by the MTT assay to screen out a drug with the most broad-spectrum and strongest synergistic anti-glioma activity." | 7.96 | Silver Nanotriangles and Chemotherapeutics Synergistically Induce Apoptosis in Glioma Cells via a ROS-Dependent Mitochondrial Pathway. ( Cao, Y; Chen, W; Li, D; Liu, P; Ma, J; Yang, H; Zhao, J, 2020) |
| "It was unknown whether the combination of cryotherapy and 5-fluorouracil (5-FU) could produce a synergistic effect, though both of them could induce apoptosis of glioma cells." | 7.72 | [Effect of cryotherapy and 5-fluorouracil on apoptosis of G422 glioma cells]. ( Huang, KM; Li, XJ; Qin, J; Tu, HJ; Wang, H; Wang, LC; Zhou, ZM, 2004) |
| " In this study the effects of intracarotid infusion of LTE4 on blood-tumor barrier (BTB) permeability for intravenously administered 14C-aminoisobutyric acid, 14C-5-fluorouracil (5-FU) 14C-sucrose and 3H-methotrexate (MTX) were examined in C6 gliomas of rats." | 7.69 | Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats. ( Chio, CC; Lin, MT; Lin, SJ, 1995) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 7.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "The effects of the two antitumor drugs vinblastine and 5-fluorouracil on the growth of the human tumor cell lines U-118 MG (glioma) and HTh-7 (thyroid cancer) were analyzed." | 7.67 | Effects of vinblastine and 5-fluorouracil on human glioma and thyroid cancer cell monolayers and spheroids. ( Nederman, T, 1984) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 7.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 7.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "For patients who have significant residual tumor after resection or relapse after radiation, the proper chemotherapy regimen has not yet been identified." | 6.72 | Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. ( Ahn, SD; Ghim, TT; Goo, HW; Khang, SK; Kim, YJ; Lee, MJ; Park, JB; Ra, YS; Song, JS, 2006) |
| "5-Fluorouracil (5-FU) was selected for encapsulation, because this hydrophilic and antimetabolic drug is not directly neurotoxic and does not readily cross the blood-brain barrier." | 5.29 | Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. ( Benoit, JP; Boisdron-Celle, M; Croué, A; Guy, G; Menei, P, 1996) |
| "We conducted a phase I study to estimate the maximum tolerated dose and describe the dose-limiting toxicities and pharmacokinetics of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy to children with newly diagnosed brainstem or high-grade gliomas." | 5.17 | Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. ( Banerjee, A; Blaney, SM; Boyett, JM; Brownstein, C; Chintagumpala, M; Gururangan, S; Hussain, S; Kilburn, LB; Kocak, M; Kun, L; Meneses-Lorente, G; Paulino, AC; Schaedeli Stark, F; Thompson, PA, 2013) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| " The strategy was evaluated initially to provide localized and sustained delivery of the radiosensitizer 5-fluorouracil (5-FU) after patients underwent surgical resection of malignant glioma." | 5.11 | Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. ( Benoit, JP; Boisdron-Celle, M; Delhaye, M; Faisant, N; Fournier, D; Jadaud, E; Menei, P; Michalak, S, 2004) |
| "This study was a randomized, multicenter Phase II trial comparing the effect of perioperative implantation of 5-fluorouracil-releasing microspheres followed by early radiotherapy (Arm A) and early radiotherapy alone (Arm B) in patients with gross total resection of high-grade glioma." | 5.11 | Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. ( Assaker, R; Bataille, B; Bauchet, L; Benoit, JP; Capelle, L; Dorwling-Carter, D; Faisant, N; François, P; Fuentes, S; Guyotat, J; Menei, P; Paquis, P; Parker, F; Sabatier, J, 2005) |
| "Fourteen patients with malignant gliomas were entered on a phase II study of 5-fluorouracil 300-370 mg/m2 plus folinic acid 200 mg/m2 x 5 days q4 weeks." | 5.08 | A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. ( Dahrouge, S; Soltys, K; Stewart, DJ, 1995) |
| "This Phase III trial tested the efficacy and safety of intra-arterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) for the treatment of newly resected malignant glioma, comparing intra-arterial BCNU and intravenous BCNU (200 mg/sq m every 8 weeks), each regimen without or with intravenous 5-fluorouracil (1 gm/sq m three times daily given 2 weeks after BCNU)." | 5.07 | A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohff, J; Robertson, JT; Selker, RG; Shapiro, WR; VanGilder, JC, 1992) |
| " The anti-glioma effect of cyclophosphamide (CTX), 5-fluorouracil (5-FU), oxaliplatin (OXA), doxorubicin (DOX) or gemcitabine (GEM) combined with AgNTs in different glioma cell lines (U87, U251 and C6) was assessed by the MTT assay to screen out a drug with the most broad-spectrum and strongest synergistic anti-glioma activity." | 3.96 | Silver Nanotriangles and Chemotherapeutics Synergistically Induce Apoptosis in Glioma Cells via a ROS-Dependent Mitochondrial Pathway. ( Cao, Y; Chen, W; Li, D; Liu, P; Ma, J; Yang, H; Zhao, J, 2020) |
| "5FC, 5-fluorocytosineBBB, Basso, Beattie, and BresnahanCD, cytosine deaminaseDP, diastolic blood pressureGCV, ganciclovir; hNSCs, human neural stem cellsISCG, intramedullary spinal cord gliomasMAP, mean arterial blood pressureNSCs, neural stem cellsSP, systolic blood pressureTK, thymidine kinase." | 3.83 | Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells. ( Abd-El-Barr, M; Aljuboori, Z; Anderson, JE; Chi, JH; Han, I; Haragopal, H; Kim, SU; Lee, HJ; Ropper, AE; Sidman, RL; Snyder, EY; Teng, YD; Viapiano, MS; Zeng, X, 2016) |
| "Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors." | 3.72 | Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. ( Barresi, V; Belluardo, N; Cattaneo, E; Condorelli, DF; Mudò, G; Sipione, S, 2003) |
| "It was unknown whether the combination of cryotherapy and 5-fluorouracil (5-FU) could produce a synergistic effect, though both of them could induce apoptosis of glioma cells." | 3.72 | [Effect of cryotherapy and 5-fluorouracil on apoptosis of G422 glioma cells]. ( Huang, KM; Li, XJ; Qin, J; Tu, HJ; Wang, H; Wang, LC; Zhou, ZM, 2004) |
| "To evaluate an intracranial polymer implant containing bromodeoxyuridine (BrdUrd) and N-(phosphonacetyl)-L-aspartic acid (PALA) in combination with external beam radiotherapy (EBRT) in the treatment of a rat glioma." | 3.72 | Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy. ( Lehnert, S; Li, Y; Owusu, A, 2004) |
| " 5-Fluorouracil microspheres were formulated by an emulsion-extraction method, and evaluated on a C6 glioma model." | 3.72 | Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. ( Benoit, JP; Colin, N; Fournier, E; Lemaire, L; Menei, P; Passirani, C; Sagodira, S; Vonarbourg, A, 2003) |
| "Murine glioma 261 (Gl261) cells were transduced with an adenoviral vector (Adex-CAUPTK) encoding both uracil phosphoribosyltransferase and thymidine kinase genes which sensitise cells to 5-fluorouracil (5-FU) and ganciclovir (GC), respectively." | 3.72 | Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model. ( Desaknai, S; Esik, O; Hamada, H; Lumniczky, K; Safrany, G, 2003) |
| "Spectral analysis could distinguish tumour kinetics from normal tissue kinetics in an individual [11C]-temozolomide study and demonstrated a markedly greater volume of distribution (VD) in glioma than in normal brain, although there was no appreciable difference in mean residence time." | 3.70 | Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. ( Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P, 1998) |
| " In this study the effects of intracarotid infusion of LTE4 on blood-tumor barrier (BTB) permeability for intravenously administered 14C-aminoisobutyric acid, 14C-5-fluorouracil (5-FU) 14C-sucrose and 3H-methotrexate (MTX) were examined in C6 gliomas of rats." | 3.69 | Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats. ( Chio, CC; Lin, MT; Lin, SJ, 1995) |
| " We have treated 18 recurrent glioma patients with high dose methotrexate (HDMTX) plus 5-fluorouracil (5FU)." | 3.68 | Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). ( Boiardi, A; Croci, D; Perego, E; Silvani, A; Solero, CL, 1992) |
| "Four chemotherapeutic agents (cyclophosphamide, 5-fluorouracil (5-FU), methotrexate (MTX), and bleomycin) were given intravenously to rats harboring the avian sarcoma virus-induced glioma." | 3.67 | Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. ( Barnett, PA; Frenkel, EP; Neuwelt, EA, 1984) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 3.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "The effects of the two antitumor drugs vinblastine and 5-fluorouracil on the growth of the human tumor cell lines U-118 MG (glioma) and HTh-7 (thyroid cancer) were analyzed." | 3.67 | Effects of vinblastine and 5-fluorouracil on human glioma and thyroid cancer cell monolayers and spheroids. ( Nederman, T, 1984) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 3.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 3.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "The penetration of [3H]thymidine, [3H]D-leucine, [125I]albumin, and the drugs [3H]5-fluorouracil and [3H]vinblastine into human glioma spheroids (in vitro tumor models) was studied by a method based on rapid freezing, freeze drying, vapor fixation, wax embedding, dry sectioning, and contact autoradiography." | 3.66 | Penetration of substances into tumor tissue--a methodological study on cellular spheroids. ( Carlsson, J; Malmqvist, M; Nederman, T, 1981) |
| "For patients who have significant residual tumor after resection or relapse after radiation, the proper chemotherapy regimen has not yet been identified." | 2.72 | Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children. ( Ahn, SD; Ghim, TT; Goo, HW; Khang, SK; Kim, YJ; Lee, MJ; Park, JB; Ra, YS; Song, JS, 2006) |
| "High-grade gliomas are extremely difficult to treat because they are invasive and therefore not curable by surgical resection; the toxicity of current chemo- and radiation therapies limits the doses that can be used." | 1.39 | Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies. ( Aboody, KS; Annala, AJ; Aramburo, S; Badie, B; Barish, ME; Blanchard, S; Brown, CE; Couture, LA; D'Apuzzo, M; Frank, RT; Garcia, E; Gutova, M; Kim, SU; Metz, MZ; Moats, RA; Najbauer, J; Portnow, J; Synold, TW; Valenzuela, VV, 2013) |
| " Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage." | 1.38 | Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. ( Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012) |
| "5-Fluorouracil (5-FU) was selected for encapsulation, because this hydrophilic and antimetabolic drug is not directly neurotoxic and does not readily cross the blood-brain barrier." | 1.29 | Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. ( Benoit, JP; Boisdron-Celle, M; Croué, A; Guy, G; Menei, P, 1996) |
| " A biphasic dose-response curve for 5-FU was also obtained for cells in these tumors, indicating the presence of 5-FU resistant cells." | 1.28 | [Analysis on combined effect of X-rays with 5-FU on rat subcutaneous gliomas]. ( Katakura, R; Sasaki, T; Suzuki, J; Takahashi, K; Yoshimoto, T, 1992) |
| "The authors treated 10 cases of malignant gliomas with intra-arterial chemotherapy after osmotic blood-brain barrier disruption." | 1.28 | [Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption]. ( Hosoya, T; Nakai, O; Takahama, H; Takanashi, T; Yamada, K, 1989) |
| "A previously published protocol for treating recurrent malignant gliomas with sequential courses of BCNU and 5-FU was partially planned based upon these initial observations." | 1.27 | Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil. ( Dougherty, DV; Gerosa, MA; Rosenblum, ML; Wilson, CB, 1983) |
| " Both dosage and releasing time can be adjusted." | 1.27 | [Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites]. ( Himuro, H; Inoue, N; Kaetsu, I; Kitamura, K; Kubo, O; Sakairi, M; Tajika, T; Tajika, Y; Tohyama, T; Yoshida, M, 1986) |
| "Both EB and HRP penetrated the brain tumors but did not stain the normal brain tissues." | 1.27 | Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor. ( Fukui, M; Inoue, T; Kitamura, K; Nagara, H; Nishio, S, 1987) |
| "In those with metastatic brain tumors, the median survival time was 280 days, 1-year survival rate 43." | 1.27 | [Clinical application of a sustained release anticancer pellet]. ( Aoyama, I; Handa, H; Hashi, K; Kamijyo, Y; Mori, K; Oda, Y; Okumura, T; Tokuriki, Y; Yamashita, J, 1985) |
| " In vitro studies showed that 5-FC combined with CDase induced significant growth-inhibitory effects on the cultured glioma cells." | 1.27 | Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. ( Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (43.81) | 18.7374 |
| 1990's | 16 (15.24) | 18.2507 |
| 2000's | 22 (20.95) | 29.6817 |
| 2010's | 17 (16.19) | 24.3611 |
| 2020's | 4 (3.81) | 2.80 |
| Authors | Studies |
|---|---|
| Mohler, ML | 1 |
| Kang, GS | 1 |
| Hong, SS | 1 |
| Patil, R | 1 |
| Kirichenko, OV | 1 |
| Li, W | 1 |
| Rakov, IM | 1 |
| Geisert, EE | 1 |
| Miller, DD | 1 |
| Kiser, K | 1 |
| Zhang, J | 2 |
| Das, AB | 1 |
| Tranos, JA | 1 |
| Wadghiri, YZ | 1 |
| Kim, SG | 1 |
| Pan, YB | 1 |
| Wang, S | 1 |
| He, X | 1 |
| Tang, W | 1 |
| Wang, J | 1 |
| Shao, A | 1 |
| Yang, H | 4 |
| Chen, W | 1 |
| Ma, J | 1 |
| Zhao, J | 1 |
| Li, D | 1 |
| Cao, Y | 1 |
| Liu, P | 1 |
| Romena, G | 1 |
| Nguyen, L | 1 |
| Berg, K | 2 |
| Madsen, SJ | 1 |
| Hirschberg, H | 2 |
| Huang, D | 1 |
| Wang, G | 1 |
| Mao, J | 1 |
| Liu, C | 1 |
| Fan, Z | 1 |
| Zhang, Y | 2 |
| Zhang, B | 1 |
| Zhao, Y | 1 |
| Dai, C | 1 |
| He, Y | 1 |
| Ma, H | 1 |
| Liu, G | 1 |
| Chen, X | 1 |
| Zhao, Q | 1 |
| Cloughesy, TF | 2 |
| Landolfi, J | 2 |
| Vogelbaum, MA | 2 |
| Ostertag, D | 4 |
| Elder, JB | 2 |
| Bloomfield, S | 2 |
| Carter, B | 2 |
| Chen, CC | 2 |
| Kalkanis, SN | 2 |
| Kesari, S | 2 |
| Lai, A | 2 |
| Lee, IY | 2 |
| Liau, LM | 2 |
| Mikkelsen, T | 2 |
| Nghiemphu, P | 1 |
| Piccioni, D | 2 |
| Accomando, W | 1 |
| Diago, OR | 3 |
| Hogan, DJ | 3 |
| Gammon, D | 3 |
| Kasahara, N | 4 |
| Kheoh, T | 1 |
| Jolly, DJ | 5 |
| Gruber, HE | 5 |
| Das, A | 3 |
| Walbert, T | 2 |
| Zhu, JJ | 1 |
| Haghighi, A | 1 |
| Lu, G | 1 |
| Carvalho, LA | 1 |
| Teng, J | 1 |
| Fleming, RL | 1 |
| Tabet, EI | 1 |
| Zinter, M | 1 |
| de Melo Reis, RA | 1 |
| Tannous, BA | 1 |
| Sun, CH | 1 |
| Kilburn, LB | 1 |
| Kocak, M | 1 |
| Schaedeli Stark, F | 1 |
| Meneses-Lorente, G | 1 |
| Brownstein, C | 1 |
| Hussain, S | 1 |
| Chintagumpala, M | 1 |
| Thompson, PA | 1 |
| Gururangan, S | 1 |
| Banerjee, A | 1 |
| Paulino, AC | 1 |
| Kun, L | 1 |
| Boyett, JM | 1 |
| Blaney, SM | 1 |
| Aboody, KS | 1 |
| Najbauer, J | 1 |
| Metz, MZ | 1 |
| D'Apuzzo, M | 1 |
| Gutova, M | 1 |
| Annala, AJ | 1 |
| Synold, TW | 1 |
| Couture, LA | 1 |
| Blanchard, S | 1 |
| Moats, RA | 1 |
| Garcia, E | 1 |
| Aramburo, S | 1 |
| Valenzuela, VV | 1 |
| Frank, RT | 1 |
| Barish, ME | 1 |
| Brown, CE | 1 |
| Kim, SU | 3 |
| Badie, B | 1 |
| Portnow, J | 1 |
| Laquintana, V | 1 |
| Denora, N | 1 |
| Lopalco, A | 1 |
| Lopedota, A | 1 |
| Cutrignelli, A | 1 |
| Lasorsa, FM | 1 |
| Agostino, G | 1 |
| Franco, M | 1 |
| Takahashi, M | 1 |
| Valdes, G | 1 |
| Hiraoka, K | 1 |
| Inagaki, A | 1 |
| Kamijima, S | 1 |
| Micewicz, E | 1 |
| Robbins, JM | 3 |
| McBride, WH | 1 |
| Iwamoto, KS | 1 |
| Funaro, MG | 1 |
| Nemani, KV | 1 |
| Chen, Z | 1 |
| Bhujwalla, ZM | 1 |
| Griswold, KE | 1 |
| Gimi, B | 1 |
| Ropper, AE | 1 |
| Zeng, X | 1 |
| Haragopal, H | 1 |
| Anderson, JE | 1 |
| Aljuboori, Z | 1 |
| Han, I | 1 |
| Abd-El-Barr, M | 1 |
| Lee, HJ | 1 |
| Sidman, RL | 1 |
| Snyder, EY | 1 |
| Viapiano, MS | 1 |
| Chi, JH | 1 |
| Teng, YD | 1 |
| Nghiemphu, PL | 1 |
| Chu, A | 1 |
| Hanna, M | 1 |
| McCarthy, D | 1 |
| Mitchell, L | 1 |
| Rodriguez-Aguirre, M | 1 |
| Zhu, H | 1 |
| Chen, J | 1 |
| Qiu, J | 1 |
| Huang, K | 1 |
| Wu, M | 1 |
| Xia, C | 1 |
| Lv, SQ | 2 |
| Zhang, KB | 1 |
| Zhang, EE | 1 |
| Gao, FY | 1 |
| Yin, CL | 1 |
| Huang, CJ | 1 |
| He, JQ | 2 |
| Ren, Y | 1 |
| Kang, CS | 1 |
| Yuan, XB | 1 |
| Zhou, X | 1 |
| Xu, P | 1 |
| Han, L | 1 |
| Wang, GX | 1 |
| Jia, Z | 1 |
| Zhong, Y | 1 |
| Yu, S | 1 |
| Sheng, J | 1 |
| Pu, PY | 1 |
| Amundson, KK | 1 |
| Lopez Espinoza, F | 1 |
| Martin, B | 1 |
| Buckley, T | 1 |
| Galvão da Silva, AP | 1 |
| Lin, AH | 1 |
| Valenta, DT | 1 |
| Perez, OD | 1 |
| Ibañez, CE | 1 |
| Chen, CI | 1 |
| Pettersson, PL | 1 |
| Burnett, R | 1 |
| Daublebsky, V | 1 |
| Hlavaty, J | 1 |
| Gunzburg, W | 1 |
| Kim, JH | 1 |
| Kim, JY | 1 |
| Cho, KG | 1 |
| Zhang, QS | 1 |
| Zhang, M | 1 |
| Liang, SJ | 1 |
| Lin, HZ | 1 |
| Ji, T | 1 |
| Li, WP | 1 |
| Barresi, V | 1 |
| Belluardo, N | 1 |
| Sipione, S | 1 |
| Mudò, G | 1 |
| Cattaneo, E | 1 |
| Condorelli, DF | 1 |
| Desaknai, S | 1 |
| Lumniczky, K | 1 |
| Esik, O | 1 |
| Hamada, H | 1 |
| Safrany, G | 1 |
| Wang, B | 1 |
| Yoshimura, I | 1 |
| Liu, YS | 2 |
| Fournier, E | 2 |
| Passirani, C | 2 |
| Montero-Menei, C | 2 |
| Colin, N | 2 |
| Breton, P | 1 |
| Sagodira, S | 2 |
| Menei, P | 8 |
| Benoit, JP | 9 |
| Reardon, DA | 1 |
| Friedman, HS | 1 |
| Powell, JB | 1 |
| Gilbert, M | 1 |
| Yung, WK | 3 |
| Westphal, M | 1 |
| Tonn, JC | 1 |
| Vonarbourg, A | 1 |
| Lemaire, L | 4 |
| Jadaud, E | 1 |
| Faisant, N | 2 |
| Boisdron-Celle, M | 2 |
| Michalak, S | 1 |
| Fournier, D | 1 |
| Delhaye, M | 1 |
| Li, Y | 1 |
| Owusu, A | 1 |
| Lehnert, S | 1 |
| Wang, H | 1 |
| Tu, HJ | 1 |
| Qin, J | 1 |
| Li, XJ | 1 |
| Huang, KM | 1 |
| Zhou, ZM | 1 |
| Wang, LC | 1 |
| Roullin, VG | 3 |
| Mege, M | 1 |
| Cueyssac, JP | 1 |
| Venier-Julienne, MC | 3 |
| Gamelin, E | 1 |
| Conrad, C | 1 |
| Miller, CR | 1 |
| Ji, Y | 1 |
| Gomez-Manzano, C | 1 |
| Bharara, S | 1 |
| McMurray, JS | 1 |
| Lang, FF | 1 |
| Wong, F | 1 |
| Sawaya, R | 1 |
| Fueyo, J | 1 |
| Capelle, L | 1 |
| Guyotat, J | 1 |
| Fuentes, S | 1 |
| Assaker, R | 1 |
| Bataille, B | 1 |
| François, P | 1 |
| Dorwling-Carter, D | 1 |
| Paquis, P | 1 |
| Bauchet, L | 1 |
| Parker, F | 1 |
| Sabatier, J | 1 |
| Lü, SQ | 1 |
| Venier, MC | 1 |
| Lee, MJ | 1 |
| Ra, YS | 1 |
| Park, JB | 1 |
| Goo, HW | 1 |
| Ahn, SD | 1 |
| Khang, SK | 1 |
| Song, JS | 1 |
| Kim, YJ | 1 |
| Ghim, TT | 1 |
| Lee, KC | 1 |
| Hamstra, DA | 1 |
| Bhojani, MS | 1 |
| Khan, AP | 1 |
| Ross, BD | 1 |
| Rehemtulla, A | 1 |
| Hau, P | 1 |
| Kunz-Schughart, L | 1 |
| Bogdahn, U | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
| Kitahara, M | 4 |
| Katakura, R | 5 |
| Mori, T | 4 |
| Suzuki, J | 5 |
| Sasaki, T | 7 |
| Levin, VA | 8 |
| Edwards, MS | 2 |
| Wara, WM | 1 |
| Allen, J | 1 |
| Ortega, J | 1 |
| Vestnys, P | 1 |
| Tsuchida, T | 1 |
| Watanabe, E | 1 |
| Nakayama, H | 1 |
| Sasaki, A | 1 |
| Nakamura, S | 1 |
| Sasaki, M | 1 |
| Fujiwara, T | 2 |
| Nemoto, S | 1 |
| Fujiwara, K | 1 |
| Yanagibashi, K | 1 |
| Hayakawa, I | 1 |
| Nomura, K | 1 |
| Harada, K | 1 |
| Okamoto, H | 1 |
| Kiya, K | 1 |
| Fujioka, Y | 1 |
| Uozumi, T | 1 |
| Kodama, Y | 1 |
| Matsumoto, K | 1 |
| Tabuchi, K | 2 |
| Furuta, T | 1 |
| Nakasone, S | 1 |
| Ohnishi, R | 1 |
| Moriya, Y | 1 |
| Nishimoto, A | 1 |
| Doi, A | 1 |
| Asari, S | 1 |
| Neuwelt, EA | 1 |
| Barnett, PA | 1 |
| Frenkel, EP | 1 |
| Ishiwata, K | 1 |
| Ido, T | 1 |
| Takahashi, T | 1 |
| Monma, M | 1 |
| Iwata, R | 1 |
| Abe, Y | 1 |
| Matsuzawa, T | 1 |
| Tsurumi, Y | 1 |
| Kameyama, M | 1 |
| Carlsson, J | 2 |
| Nederman, T | 3 |
| Merry, S | 1 |
| Kaye, SB | 1 |
| Freshney, RI | 2 |
| Penn, RD | 1 |
| Kroin, JS | 1 |
| Harris, JE | 1 |
| Chiu, KM | 1 |
| Braun, DP | 1 |
| Gerosa, MA | 1 |
| Dougherty, DV | 1 |
| Wilson, CB | 4 |
| Rosenblum, ML | 1 |
| Vestnys, PS | 1 |
| Malmqvist, M | 1 |
| Stewart, DJ | 1 |
| Dahrouge, S | 1 |
| Soltys, K | 1 |
| Greenberg, HS | 2 |
| Chandler, WF | 1 |
| Ensminger, WD | 2 |
| Sandler, H | 1 |
| Junck, L | 1 |
| Page, MA | 1 |
| Crane, D | 1 |
| McKeever, P | 1 |
| Tankanow, R | 1 |
| Bromberg, J | 1 |
| Yamashima, T | 1 |
| Ohnishi, T | 1 |
| Nakajima, Y | 1 |
| Terasaki, T | 1 |
| Tanaka, M | 2 |
| Yamashita, J | 2 |
| Tsuji, A | 1 |
| Chio, CC | 1 |
| Lin, SJ | 1 |
| Lin, MT | 1 |
| Croué, A | 1 |
| Guy, G | 1 |
| Shimura, T | 1 |
| Teramoto, A | 1 |
| Aihara, K | 1 |
| Meikle, SR | 1 |
| Matthews, JC | 1 |
| Brock, CS | 1 |
| Wells, P | 1 |
| Harte, RJ | 1 |
| Cunningham, VJ | 1 |
| Jones, T | 1 |
| Price, P | 1 |
| Nakagawa, H | 1 |
| Yamada, M | 1 |
| Fukushima, M | 1 |
| Shimizu, K | 1 |
| Ikenaka, K | 1 |
| Xu, LF | 1 |
| Ge, K | 1 |
| Zheng, ZC | 1 |
| Sun, LY | 1 |
| Liu, XY | 1 |
| Hess, KR | 1 |
| Wong, ET | 1 |
| Jaeckle, KA | 1 |
| Kyritsis, AP | 1 |
| Prados, MD | 2 |
| Franconi, F | 1 |
| Jallet, P | 1 |
| Le Jeune, JJ | 1 |
| Deverre, JR | 1 |
| Hindré, F | 1 |
| Vienet, R | 1 |
| Takeuchi, K | 1 |
| Wilkinson, HA | 1 |
| Kornblith, P | 1 |
| Weems, S | 1 |
| Walker, MD | 1 |
| Kirsch, WM | 1 |
| Van Buskirk, JJ | 1 |
| Schulz, DW | 1 |
| Hoffman, WF | 1 |
| Pischer, TL | 1 |
| Seager, ML | 1 |
| Boldrey, EB | 1 |
| Prasad, KN | 1 |
| Sinha, PK | 1 |
| Ramanujam, M | 1 |
| Sakamoto, A | 1 |
| Oda, Y | 2 |
| Tokuriki, Y | 2 |
| Tsuda, E | 1 |
| Handa, H | 2 |
| Kieler, J | 1 |
| Fukawa, O | 1 |
| Sato, T | 1 |
| Hori, S | 1 |
| Morgan, D | 1 |
| Diemath, HE | 1 |
| Boiardi, A | 1 |
| Silvani, A | 1 |
| Croci, D | 1 |
| Perego, E | 1 |
| Solero, CL | 1 |
| Shapiro, WR | 5 |
| Takahashi, K | 2 |
| Yoshimoto, T | 1 |
| Green, SB | 1 |
| Burger, PC | 1 |
| Selker, RG | 1 |
| VanGilder, JC | 1 |
| Robertson, JT | 1 |
| Mealey, J | 1 |
| Ransohff, J | 1 |
| Mahaley, MS | 1 |
| Mancini, WR | 1 |
| Stetson, PL | 1 |
| Lawrence, TS | 1 |
| Wagner, JG | 1 |
| Yamashita, M | 1 |
| Hashimoto, T | 1 |
| Hirakawa, T | 1 |
| Fukushima, T | 1 |
| Tomonaga, M | 1 |
| Hara, Y | 1 |
| Kono, A | 1 |
| Kawakami, K | 1 |
| Kawamoto, K | 2 |
| Oka, N | 1 |
| Kawamura, Y | 2 |
| Matsumura, H | 2 |
| Ito, T | 2 |
| Ohyama, A | 2 |
| Kuwahara, K | 2 |
| Yamada, K | 1 |
| Takahama, H | 1 |
| Nakai, O | 1 |
| Takanashi, T | 1 |
| Hosoya, T | 1 |
| Phuphanich, S | 1 |
| Liu, HC | 1 |
| Da Silva, V | 1 |
| Murovic, J | 1 |
| Choucair, A | 1 |
| Chamberlain, M | 1 |
| Berger, M | 1 |
| Seager, M | 1 |
| Davis, RL | 1 |
| Kubo, O | 1 |
| Himuro, H | 1 |
| Inoue, N | 1 |
| Tajika, Y | 1 |
| Tajika, T | 1 |
| Tohyama, T | 1 |
| Sakairi, M | 1 |
| Yoshida, M | 1 |
| Kaetsu, I | 1 |
| Kitamura, K | 2 |
| Shapiro, JR | 1 |
| Inoue, T | 1 |
| Fukui, M | 1 |
| Nishio, S | 1 |
| Nagara, H | 1 |
| Sugiyama, S | 1 |
| Mashiyama, S | 1 |
| Kanno, S | 1 |
| Rodriguez, LA | 1 |
| Prados, M | 1 |
| Fulton, D | 1 |
| Silver, P | 1 |
| Levin, V | 1 |
| Kamijyo, Y | 1 |
| Okumura, T | 1 |
| Aoyama, I | 1 |
| Hashi, K | 1 |
| Mori, K | 1 |
| Nishiyama, T | 1 |
| Yamamoto, N | 1 |
| Katsuragi, T | 1 |
| Sakai, T | 1 |
| Broder, LE | 1 |
| Rall, DP | 1 |
| Sano, K | 1 |
| Hoshino, T | 1 |
| Nagai, M | 1 |
| Chadwick, M | 1 |
| Little, AD | 1 |
| Heiss, WD | 1 |
| Kroiss, A | 1 |
| Kühböck, J | 1 |
| Profanter, W | 1 |
| Sutton, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC[NCT01470794] | Phase 1 | 58 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma[NCT01156584] | Phase 1 | 54 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende[NCT01985256] | Phase 1 | 17 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for fluorouracil and Glial Cell Tumors
| Article | Year |
|---|---|
Irinotecan: promising activity in the treatment of malignant glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2003 |
Drug delivery into the brain using poly(lactide-co-glycolide) microspheres.
Topics: Animals; Antimetabolites, Antineoplastic; Biocompatible Materials; Brain; Cell Transplantation; Clin | 2005 |
The biologic basis of malignant brain tumor therapy.
Topics: Animals; BCG Vaccine; Brain Neoplasms; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm; | 1976 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Chemotherapy of brain tumors.
Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug | 1972 |
15 trials available for fluorouracil and Glial Cell Tumors
| Article | Year |
|---|---|
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Topics: Antimetabolites; Brain Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flu | 2018 |
Molecular Analyses Support the Safety and Activity of Retroviral Replicating Vector Toca 511 in Patients.
Topics: Aged; Animals; Autopsy; Cell Line, Tumor; Cytosine Deaminase; Disease Models, Animal; Female; Flucyt | 2018 |
Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Brain Stem Neoplasms; Capecitabine; Chemoradioth | 2013 |
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Topics: Confidence Intervals; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Vectors; Glioma; Prodru | 2016 |
Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Delivery Systems; Drug Implant | 2004 |
Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial.
Topics: Antimetabolites, Antineoplastic; Biodegradation, Environmental; Combined Modality Therapy; Delayed-A | 2005 |
Effectiveness of novel combination chemotherapy, consisting of 5-fluorouracil, vincristine, cyclophosphamide and etoposide, in the treatment of low-grade gliomas in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool | 2006 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Female; Fluorouracil; Glioblastoma; Glioma; Humans; Infus | 1995 |
Radiosensitization with carotid intra-arterial bromodeoxyuridine +/- 5-fluorouracil biomodulation for malignant gliomas.
Topics: Adult; Aged; Brain Neoplasms; Bromodeoxyuridine; Fluorouracil; Glioma; Humans; Infusions, Intra-Arte | 1994 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
Chemotherapy: adjuvant to surgery and radiation therapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Fluorouracil; Glioma; | 1975 |
Chemotherapy of malignant gliomas: studies of the BTCG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplatin; Combined Mod | 1992 |
A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 1992 |
85 other studies available for fluorouracil and Glial Cell Tumors
| Article | Year |
|---|---|
Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues.
Topics: Animals; Antineoplastic Agents; Astrocytes; Biphenyl Compounds; Cell Line, Tumor; Cells, Cultured; D | 2006 |
Evaluation of cellular water exchange in a mouse glioma model using dynamic contrast-enhanced MRI with two flip angles.
Topics: Animals; Bevacizumab; Contrast Media; Fluorouracil; Glioma; Magnetic Resonance Imaging; Mice; Water | 2023 |
A combination of glioma in vivo imaging and in vivo drug delivery by metal-organic framework based composite nanoparticles.
Topics: Animals; Cell Line, Tumor; Fluorouracil; Glioma; Heterografts; Humans; Imidazoles; Magnetic Resonanc | 2019 |
Silver Nanotriangles and Chemotherapeutics Synergistically Induce Apoptosis in Glioma Cells via a ROS-Dependent Mitochondrial Pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Fluorouracil; Gli | 2020 |
Enhanced gene transfection of macrophages by photochemical internalization: Potential for gene-directed enzyme prodrug therapy of gliomas.
Topics: Animals; Cell Line, Tumor; Cytosine Deaminase; Fluorouracil; Glioma; Humans; Macrophages; Photochemo | 2021 |
Intravital Whole-Process Monitoring Thermo-Chemotherapy Via 2D Silicon Nanoplatform: A Macro Guidance and Long-Term Microscopic Precise Imaging Strategy.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Disease Models, Animal; Fluorouracil; Gli | 2021 |
Olfactory Ensheathing Cells: A Trojan Horse for Glioma Gene Therapy.
Topics: Administration, Intranasal; Animals; Cytosine Deaminase; Female; Flucytosine; Fluorouracil; Genetic | 2019 |
Photochemical Internalization Enhanced Nonviral Suicide Gene Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Fluorou | 2019 |
Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
Topics: Animals; Cell Line; Cytosine Deaminase; Female; Flow Cytometry; Flucytosine; Fluorouracil; Glioma; H | 2013 |
Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Calorimetry, Differential Scanning; Carrier Proteins; Ce | 2014 |
Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.
Topics: Animals; Cell Line, Tumor; Cell Survival; Cytosine Deaminase; Disease Models, Animal; Dose-Response | 2014 |
Effect of alginate microencapsulation on the catalytic efficiency and in vitro enzyme-prodrug therapeutic efficacy of cytosine deaminase and of recombinant E. coli expressing cytosine deaminase.
Topics: Alginates; Animals; Cell Line, Tumor; Cells, Immobilized; Cytosine Deaminase; Enzymes, Immobilized; | 2016 |
Targeted Treatment of Experimental Spinal Cord Glioma With Dual Gene-Engineered Human Neural Stem Cells.
Topics: Animals; Cytosine Deaminase; Flucytosine; Fluorouracil; Ganciclovir; Genetic Engineering; Genetic Th | 2016 |
IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Topics: Agammaglobulinaemia Tyrosine Kinase; Blotting, Western; Cell Line; Cell Movement; Cell Proliferation | 2017 |
Antitumor efficiency of the cytosine deaminase/5-fluorocytosine suicide gene therapy system on malignant gliomas: an in vivo study.
Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cytosine Deaminase; DNA Primers; Es | 2009 |
Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Den | 2010 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Therapeutic effect of genetically modified human neural stem cells encoding cytosine deaminase on experimental glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Combined Modality Therapy; Cytosine Deami | 2012 |
[Effects of myxoma virus on gliomas of rats models in vivo].
Topics: Animals; Brain Neoplasms; Disease Models, Animal; Female; Fluorouracil; Glioma; Male; Myxoma virus; | 2012 |
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
Topics: Animals; Brain Neoplasms; Cells, Cultured; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluoro | 2003 |
Local tumour irradiation enhances the anti-tumour effect of a double-suicide gene therapy system in a murine glioma model.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Brain Neoplasms; Cell Line | 2003 |
Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro.
Topics: Cell Death; Cell Division; Culture Media; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic The | 2003 |
Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats.
Topics: Animals; Biodegradation, Environmental; Brain Neoplasms; Carboxymethylcellulose Sodium; Drug Deliver | 2003 |
Editors' remarks: Evolving concepts for local therapies for glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; | 2003 |
Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma.
Topics: Animals; Antimetabolites, Antineoplastic; Drug Carriers; Drug Delivery Systems; Female; Fluorouracil | 2003 |
Treatment of intracranial rat glioma model with implant of radiosensitizer and biomodulator drug combined with external beam radiotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Brain Neoplasms; Bromodeoxyu | 2004 |
[Effect of cryotherapy and 5-fluorouracil on apoptosis of G422 glioma cells].
Topics: Animals; Apoptosis; Cell Line, Tumor; Cryotherapy; Fluorouracil; Glioma; HSP90 Heat-Shock Proteins; | 2004 |
Influence of 5-fluorouracil-loaded microsphere formulation on efficient rat glioma radiosensitization.
Topics: Animals; Brain; Brain Neoplasms; Drug Evaluation, Preclinical; Female; Fluorouracil; Glioma; Magneti | 2004 |
Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.
Topics: Adenoviridae; Adenovirus E1A Proteins; Base Sequence; Blotting, Western; Cell Line, Tumor; Chromatog | 2005 |
[Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro].
Topics: Brain Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Th | 2004 |
Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Diffusion Magnetic Re | 2007 |
[Combined effect of ACNU and 5-fluorouracil on spheroids of rat glioma cells].
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Dr | 1984 |
5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bra | 1984 |
[FAR therapy in brain tumors--FT207-vitamin A-Radiation therapy (author's transl)].
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Child; Child, Preschool; Drug Therapy, Combination; | 1980 |
[Pharmacokinetics study of UFT in malignant brain tumor patients].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1983 |
[Combination chemotherapy of brain tumors with ACNU and 5-FU].
Topics: Astrocytoma; Biological Products; Brain Neoplasms; Combined Modality Therapy; Drug Therapy, Combinat | 1983 |
Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery.
Topics: Animals; Antineoplastic Agents; Avian Sarcoma Viruses; Bleomycin; Blood-Brain Barrier; Brain; Brain | 1984 |
Syntheses of 18F-labeled pyrimidines and their usefulness for tumor imaging.
Topics: Animals; Chromatography, High Pressure Liquid; Floxuridine; Fluorine; Fluorouracil; Glioma; Liver Ne | 1984 |
A method to measure the radio and chemosensitivity of human spheroids.
Topics: Animals; Cell Aggregation; Cell Line; Cricetinae; Cytological Techniques; Fluorouracil; Gamma Rays; | 1983 |
Cross-resistance to cytotoxic drugs in human glioma cell lines in culture.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Dactinomycin; Doxorubicin; Drug Resistance; Fluorou | 1984 |
Chronic intratumoral chemotherapy of a rat tumor with cisplatin and fluorouracil.
Topics: Animals; Cerebellar Neoplasms; Cerebellum; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Fluo | 1983 |
Effects of vinblastine and 5-fluorouracil on human glioma and thyroid cancer cell monolayers and spheroids.
Topics: Cell Division; Cell Line; Cell Survival; Culture Techniques; Drug Evaluation, Preclinical; Fluoroura | 1984 |
Improved treatment of a brain-tumor model. Part 2: Sequential therapy with BCNU and 5-fluorouracil.
Topics: Animals; Brain Neoplasms; Carmustine; Clone Cells; Disease Models, Animal; Drug Therapy, Combination | 1983 |
Penetration of substances into tumor tissue--a methodological study on cellular spheroids.
Topics: Albumins; Biological Transport; Cell Line; Clone Cells; Fluorouracil; Glioma; Humans; Leucine; Model | 1981 |
Uptake of drugs and expression of P-glycoprotein in the rat 9L glioma.
Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological | 1993 |
Leukotriene E4 selectively increase the delivery of methotrexate to the C6 gliomas in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Autoradiography; Blood Gas Analysis; Brain Neoplasms; Caro | 1995 |
Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats.
Topics: Animals; Antimetabolites, Antineoplastic; Biodegradation, Environmental; Brain; Brain Neoplasms; Dru | 1996 |
[Histopathological and autoradiographical studies of experimental brain tumors after continuous local chemotherapy--acute stage in rat models].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autoradiography; Brain Neoplasms; Chemother | 1997 |
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; | 1998 |
[In vitro study on intrathecal application of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant tumor].
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma 256, Walker; Floxuridine; Fluor | 1998 |
[Experimental treatment of brain tumor cells using CD suicide gene].
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Escherichia coli; Flu | 1996 |
Therapeutic efficacy of 5-fluorouracil-loaded microspheres on rat glioma: a magnetic resonance imaging study.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Drug Delivery Systems; Female; Fluorourac | 2001 |
Anti-cancer drug diffusion within living rat brain tissue: an experimental study using [3H](6)-5-fluorouracil-loaded PLGA microspheres.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Brain; Brain Neoplasms; Contrast Media; Dif | 2002 |
[Role of chemotherapy in long-term survival of malignant glioma (author's transl)].
Topics: Adolescent; Adult; Astrocytoma; Bleomycin; Brain Neoplasms; Ependymoma; Female; Fluorouracil; Glioma | 1975 |
Focal chemotherapy of brain tumours using semipermeable membranes.
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Dactinomycin; Ependymoma; Fluorouracil; | 1977 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture.
Topics: Animals; Antibiotics, Antineoplastic; Ascorbic Acid; Catalase; Cell Division; Cell Survival; Cells, | 1979 |
Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in silastic.
Topics: Animals; Brain Neoplasms; Carcinoma; Drug Implants; Endopeptidases; Fluorouracil; Glioma; Humans; Ne | 1979 |
[Regression of a recurrent malignant glioma by combined chemoradiotherapy utilizing carboquone, FT-207 and telecobalt--report of a case (author's transl)].
Topics: Azirines; Brain Neoplasms; Carbazilquinone; Cobalt Radioisotopes; Drug Therapy, Combination; Fluorou | 1977 |
Radioisotopic quantitation in microtitration plates by an autofluorographic method.
Topics: Cell Line; Densitometry; Fluorometry; Fluorouracil; Glioma; Humans; Methionine; Vincristine | 1978 |
[Local and intravenous cytostatic therapy after surgery of malignant brain tumors].
Topics: Administration, Topical; Brain Neoplasms; Cyclophosphamide; Female; Fluorouracil; Glioma; Humans; In | 1977 |
Nitrosourea chemotherapy for primary malignant gliomas.
Topics: Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glioma; Humans; Lomustine; Neo | 1976 |
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle | 1992 |
Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Comb | 1992 |
[Analysis on combined effect of X-rays with 5-FU on rat subcutaneous gliomas].
Topics: Animals; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Radiation; Fluorourac | 1992 |
Variability of 5-bromo-2'-deoxyuridine incorporation into DNA of human glioma cell lines and modulation with fluoropyrimidines.
Topics: Bromodeoxyuridine; DNA, Neoplasm; Floxuridine; Fluorouracil; Glioma; Humans; Tumor Cells, Cultured | 1991 |
[5'-Deoxy-5-fluorouridine and 5-fluorouracil concentrations and thymidine phosphorylase activity in brain tumors following intravenous administration of 5'-deoxy-5-fluorouridine].
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Cerebral Ventricle Neoplasms; Child; Choroid Plexus; Epen | 1985 |
[Flow cytometric studies of brain tumors--5: New sensitivity test of antineoplastic agents for brain tumors and its clinical application].
Topics: Animals; Antineoplastic Agents; Bleomycin; Brain Neoplasms; Cell Cycle; Cell Survival; Colony-Formin | 1986 |
[Effect of combined treatment with X-irradiation and 5-fluorouracil in multicellular spheroids of rat glioma].
Topics: Animals; Combined Modality Therapy; Fluorouracil; Glioma; Rats; Tumor Cells, Cultured | 1987 |
[Intra-arterial chemotherapy of malignant glioma after osmotic blood-brain barrier disruption].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Evaluati | 1989 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
[Treatment of malignant brain tumors with slowly releasing anticancer drug-polymer composites].
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Implants; Dysge | 1986 |
Hyperosmotic blood-brain barrier disruption in brains of rats with an intracerebrally transplanted RG-C6 tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Evans Blue; Fluorouracil; Glioma; Horseradish Peroxid | 1987 |
[Biological basis for combined radio-chemotherapy in radioresistant tumors].
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Survival; Combined Modality Therapy; Fluorouracil; Glio | 1988 |
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1988 |
Combined effect of ACNU and 5-FU on rat glioma cells in spheroids and monolayer cultures.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; Fluorouraci | 1986 |
Experimental combination chemotherapy of ACNU and 5-FU against cultured glioma model (spheroid) and subcutaneous rat glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colony-Forming Units Assay; Di | 1987 |
[Clinical application of a sustained release anticancer pellet].
Topics: Antineoplastic Agents; Brain Neoplasms; Delayed-Action Preparations; Drug Administration Schedule; F | 1985 |
Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.
Topics: Animals; Brain Neoplasms; Capsules; Cytosine; Cytosine Deaminase; Drug Evaluation, Preclinical; Drug | 1985 |
Radiosensitization of brain tumor cells with a thymidine analogue (bromouridine).
Topics: Astrocytoma; Brain Neoplasms; Bromodeoxyuridine; Culture Techniques; DNA; Floxuridine; Fluorouracil; | 1968 |
Studies on the chemotherapy of experimental brain tumors: evaluation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, vincristine, and 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cyclophosphamide; Disease Models, Animal; Ependymom | 1971 |
Distribution of 5-fluorouracil-2- 14 C and its metabolites in a murine glioma.
Topics: Animals; Brain; Brain Neoplasms; Carbon Isotopes; Chromatography, Ion Exchange; Chromatography, Thin | 1972 |
[Combined cytostatic treatment of malignant brain tumors (author's transl)].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 1974 |
Tumor hyperthermia in the treatment of malignant gliomas of the brain.
Topics: Animals; Blood-Brain Barrier; Brain Edema; Brain Neoplasms; Dogs; Fluorouracil; Glioma; Hot Temperat | 1971 |
Further studies on chemotherapy of experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Ependymoma; Fluorouracil; Glioma; Mice; Neoplasms, | 1970 |